Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2026-01-20 Regulatory Filings
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
Half-Year Report on Liquidity Contract with Invest Securities
Regulatory Filings Classification · 90% confidence The document is a 'Half-Year Report on Liquidity Contract' detailing the status of a liquidity account managed by Invest Securities for OSE Immunotherapeutics. It provides specific data on share counts, cash balances, and trading volumes for the period of 01/07/2025 to 31/12/2025. While it contains financial data, it is not a full financial report (10-K or IR) nor a simple announcement of a report (RPA). It falls under the category of regulatory filings regarding share-related activities, and since it does not fit into specific categories like 'Transaction in Own Shares' (which usually refers to buybacks by the company itself rather than a liquidity contract report), 'Regulatory Filings' (RNS) is the most appropriate fallback category for this type of periodic disclosure.
2026-01-20 English
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
Regulatory Filings Classification · 95% confidence The document is a press release from OSE Immunotherapeutics announcing a new three-year strategic plan (2026-2028). It details business strategy, clinical trial progress, and financial outlook. While it discusses financial strategy, it is not a formal financial report (10-K/IR) or a specific regulatory filing. It functions as an investor-facing communication detailing corporate strategy and future outlook, which aligns best with the 'Investor Presentation' (IP) category as it outlines the company's value creation opportunities and strategic roadmap for stakeholders.
2025-12-09 English
OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur
Board/Management Information Classification · 95% confidence The document is a press release from OSE Immunotherapeutics announcing a new 3-year strategic plan (2026-2028). It details business strategy, clinical trial updates, and financial outlook. It is not a full annual report, nor is it a transcript or a simple report publication announcement (as it contains substantive strategic content). It fits best as an Investor Presentation or a general corporate strategic update, but given the specific categories, it aligns most closely with 'Investor Presentation' (IP) as it outlines the company's future value creation levers and strategic roadmap for investors.
2025-12-09 French
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
M&A Activity Classification · 95% confidence The document is a press release announcing a strategic amendment to an existing partnership agreement between OSE Immunotherapeutics and AbbVie regarding the development of a drug candidate (ABBV-230). This type of corporate announcement regarding business partnerships, licensing agreements, and strategic collaborations falls under the category of M&A Activity (TAR) as it pertains to the restructuring of a significant corporate asset/partnership agreement.
2025-12-08 English
OSE Immunotherapeutics annonce un amendement stratégique au partenariat avec AbbVie sur le développement d’ABBV-230
Regulatory Filings Classification · 95% confidence The document is a press release from OSE Immunotherapeutics announcing a strategic amendment to an existing partnership agreement with AbbVie regarding the development of a specific drug candidate (ABBV-230). It details the changes in responsibilities, financial terms, and development milestones. This type of corporate announcement regarding business partnerships and strategic agreements falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into more specific categories like M&A (which usually implies a takeover or merger) or specific financial reporting categories.
2025-12-08 French
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
Regulatory Filings Classification · 95% confidence The document is a press release issued by OSE Immunotherapeutics announcing a positive recommendation from an Independent Data Monitoring Committee (IDMC) regarding a Phase 3 clinical trial (ARTEMIA). It provides updates on clinical trial progress, patient enrollment, and future milestones. As this is a general regulatory announcement regarding company operations and clinical trial status that does not fit into specific categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2025-11-17 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.